Colleen Kelley
Overview
Dr. Kelley is a faculty member in the Division of Infectious Diseases with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health. She graduated from Emory University with her MD/MPH degree and completed her Internal Medicine residency at the University of California San Francisco and Infectious Diseases fellowship at Emory University.
Dr. Kelley has a multi-disciplinary background and previous clinical and research experience in HIV medicine, HIV epidemiology and clinical outcomes research, and laboratory-based HIV research. She sees outpatients at the Grady Infectious Disease Program and inpatients on the Infectious Diseases consult service and Special Immunology Service at Grady Memorial Hospital.
The current focus of her research is on biomedical HIV prevention interventions including pre and post-exposure prophylaxis (PrEP and PEP) and HIV vaccines. She conducts translational immunology studies of HIV susceptibility in men who have sex with men (MSM) to better understand rectal HIV transmission. Dr Kelley is a site investigator for the HIV Vaccine Trials Network at the Hope Clinic and also collaborates closely with colleagues in the School of Public Health on several HIV prevention studies including PrEP implementation projects.
Academic Appointment
- Professor of Medicine, Emory School of Medicine
- Associate Professor of Medcine, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine
- Senior Physician, Emory University School of Medicine
- Assistant Professor of Epidemiology, Department of Epidemiology, Rollins School of Public Health
Education
Degrees
- BA from University of Florida
- MD/MPH from Emory University School of Medicine
Research
Focus
- The focus of my research is HIV transmission in men who have sex with men with a recent focus on the biologic mechanisms of the disparity in HIV incidence between black and white men. In addition, I am also interested in exploring how the efficacy of biomedical HIV prevention interventions may be maximized for high-risk MSM. My approach to answer these questions generally involves translational immunology studies. I aspire to an independently funded academic research career with a focus on HIV prevention science.
Publications
-
Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.
Lancet Reg Health Am Volume: 47 Page(s): 101146
07/01/2025 Authors: Cantos VD; Ramrez BC; Kelley CF; Rio CD; Grinsztejn B -
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
EBioMedicine Volume: 117 Page(s): 105804
06/13/2025 Authors: Huang Y; Zhang L; Gelderblom H; Seaton KE; Yates NL; Paez CA; Karuna ST; Andrew P; Gamble T; Robinson ST -
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.
Lancet HIV Volume: 12 Page(s): e405 - e415
06/01/2025 Authors: Seaton KE; Paez CA; Yu C; Karuna ST; Gamble T; Miner MD; Heptinstall J; Zhang L; Gao F; Yacovone M -
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.
JAMA Netw Open Volume: 8 Page(s): e2512763
05/01/2025 Authors: Andrews LIB; Halloran ME; Neuzil KM; van der Laan L; Huang Y; Andriesen J; Patel M; Fisher LH; Janes H; Rouphael N -
Preventing Premature Pre-Exposure Prophylaxis Discontinuation and Sexually Transmitted Infections Among Men Who Have Sex With Men (Project PEACH): Protocol for a Prospective Cohort Study.
JMIR Res Protoc Volume: 14 Page(s): e56096
04/23/2025 Authors: Aldredge A; Carter D; DeCree CA; Gardner EV; Herring GB; Kaabi O; Moges-Banks R; Valencia R; Kelley CF; Sullivan PS -
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
J Infect Dis Volume: 231 Page(s): e764 - e769
04/15/2025 Authors: Wilson GJ; Church LWP; Kelley CF; Robinson ST; Lu Y; Furch BD; Fong Y; Paez CA; Yacovone M; Jacobsen T -
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
N Engl J Med Volume: 392 Page(s): 1261 - 1276
04/03/2025 Authors: Kelley CF; Acevedo-Quiones M; Agwu AL; Avihingsanon A; Benson P; Blumenthal J; Brinson C; Brites C; Cahn P; Cantos VD -
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
Clin Infect Dis
01/28/2025 Authors: Marcus JL; Weddle A; Kelley CF; Agwu A; Montalvo S; Sherman E; Vijayan T; Gutierrez J; Hickey MD; Dilworth SE -
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome.
Nat Med Volume: 31 Page(s): 207 - 217
01/01/2025 Authors: Chu VT; Glascock A; Donnell D; Grabow C; Brown CE; Ward R; Love C; Kalantar KL; Cohen SE; Cannon C -
Rectal mucosal inflammation, microbiome, and wound healing in men who have sex with men who engage in receptive anal intercourse.
Sci Rep Volume: 14 Page(s): 31598
12/30/2024 Authors: Van Doren VE; Ackerley CG; Arthur RA; Murray PM; Smith SA; Hu Y-J; Kelley CF